3-bromo-4-oxo-4-thien-2-ylbutanoic acid, 95.0%, 2.5g

Ethyl 4-(cyclopropylamino)cyclohexanecarboxylate, 97%, 1g

(R)-4-(((9h-Fluoren-9-yl)methoxy)carbonyl)piperazine-2-carboxylic acid, 95%, 1g

1-pentyl-1H-pyrazol-3-amine, 95.0%, 1g

4-[ethyl(phenyl)amino]benzaldehyde, 97%, 1g

5-Iodothiophene-2-carboxylic acid, 95.0%, 100mg

2-(Methylthio)acetamide, 99.0%, 25g

(S)-1-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)pyrrolidin-3-amine, 97%, 10mg

methyl 1-(2,2-difluoroethyl)-1H-pyrazole-3-carboxylate, 5g

1-cyclohexylpyrrolidine, 95.0%, 5g

7-BOC-2,7-DIAZABICYCLO[4.2.0]OCTANE, 95.0%, 100mg

Microliter syringe GASTIGHT® series 1700 Point type 3, 100 µl, 1710 RNR, 1 piece

Dimethyl 2-bromomalonate, 25g